CoFEND: A Cross-Modal Fusion End-to-End Network for Cold-Start Drug-Drug Interaction Prediction

๐Ÿ“… 2026-07-02
๐Ÿ“ˆ Citations: 0
โœจ Influential: 0
๐Ÿ“„ PDF
๐Ÿค– AI Summary
This work addresses the challenge of drugโ€“drug interaction (DDI) prediction in the cold-start scenario for novel drugs by proposing an end-to-end learning framework based on multimodal knowledge graphs. The authors construct four drug-centric knowledge graphs and design a four-channel graph autoencoder to jointly learn cross-modal drug similarities and DDI predictions, achieving, for the first time, their alignment within a unified framework. A two-stage interpretability mechanism is introduced to enable dual-perspective analysis of perpetrator and victim drugs. Experimental results on two real-world datasets demonstrate that the proposed method significantly outperforms existing models, achieving notable advances in both prediction accuracy and comprehensiveness of interpretability.
๐Ÿ“ Abstract
Cold-start drug-drug interaction (DDI) prediction for new drugs is critical for minimizing unexpected adverse drug reactions. The key challenge is to capture similarity between new and known drugs. However, such similarity is closely associated with complex relationships and mechanisms among drugs, enzymes, transporters, molecular structures, and other biomedical entities. Existing methods have three limitations in capturing such similarity: (1) only partial relationships and mechanisms are considered, which overlooks cross-modal information and yields incomplete or biased similarity modeling; (2) similarity computation between new and known drugs is conducted separately across modalities and performed offline for cold-start DDI prediction, leading to misalignment between similarity computation and DDI prediction; and (3) existing interpretability analyses are typically single-modality and focus primarily on key determinants of the perpetrator drug, while the underlying causes of susceptibility for the victim drug are seldom investigated. To address these issues, this paper proposes a novel Cross-Modal-Fused End-to-End Learning Network (CMF-ELN) with three components. First, diverse multimodal information is leveraged to construct four types of drug-centered knowledge graphs, enabling comprehensive similarity modeling under reconstruction-based supervision. Second, a four-channel graph autoencoder is designed to fuse cross-modal similarity within an end-to-end learning framework. Finally, a two-stage interpretability scheme is devised to precisely localize key factors for both perpetrator and victim drugs. Extensive experiments on two real datasets demonstrate that CMF-ELN achieves significantly higher prediction accuracy and more comprehensive interpretability of mechanisms than its peers.
Problem

Research questions and friction points this paper is trying to address.

cold-start
drug-drug interaction
similarity modeling
cross-modal
interpretability
Innovation

Methods, ideas, or system contributions that make the work stand out.

cross-modal fusion
end-to-end learning
cold-start DDI prediction
graph autoencoder
interpretability
๐Ÿ’ผ Related Jobs
Postdoctoral Fellow โ€“ AI-Driven Multi-Omics Integration for Predictive Toxicology
Pfizer
The annual base salary for this position ranges from $64,600.00 to $107,600.00. In addition, this position is eligible for participation in Pfizerโ€™s Global Performance Plan with a bonus target of 7.5% of the base salary. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of lifeโ€™s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site โ€“ U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States. Relocation assistance may be available based on business needs and/or eligibility.
Hybrid